Fibrinogen Concentrates Market By Type (Human, Animal) Application: General Coagulation Management, Surgery, and Others; and End User: Hospitals, ASCs, and Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Fibrinogen Concentrates market size is expected to hit around USD 6.89 billion by 2030 from valued at USD 2.98 billion in 2021 and growing at a CAGR of 8.1% from 2022 to 2030.

Fibrinogen Concentrates Market: Overview

• Fibrinogen is a soluble protein, also known as coagulation factor I in the plasma that is broken down to fibrin by the enzyme thrombin to form clots
• Human fibrinogen concentrates have been used for substitution therapy in cases of hypofibrinogenemia, dysfibrinogenemia, and afibrinogenemia. Commercially available human fibrinogen concentrate is virus-inactivated. Hence, it plays a critical role in hemostasis, especially in bleeding patients with an acquired fibrinogen deficiency.
• Rise in demand for fibrinogen among physicians as blood clot formation agents, increase in the number of cases of bleeding disorders, and surge in the availability of fibrinogen products are key factors projected to drive the global fibrinogen concentrates market during the forecast period. Furthermore, increase in investment in research & development (R&D) and large number of products under pipeline offer significant opportunities in the market.
• In November 2018, Octapharma received marketing authorization from the Swiss Agency for therapeutic products for fibryga, a lyophilized fibrinogen concentrate for intravenous infusion indicated for the treatment of congenital and acquired fibrinogen deficiencies

Report Scope of the Fibrinogen Concentrates Market

Rarity of Patient Population Creates Hurdles in Conducting Research Studies

However, it is challenging to evaluate the efficacy of human fibrinogen concentrate (FCH) in patients with congenital fibrinogen deficiency (CFD) due to the rarity of patient population. Hence, stakeholders are expected to collaborate with researchers to conduct observational retrospective study with an additional prospective component to assess the efficacy of human fibrinogen concentrate for the treatment of acute bleeding events.

It has been found that FCH is well tolerated in patients with CFD and is effective in treating bleeding events. FCH is found to be effective and has a favorable safety profile when used as treatment for both on-demand bleeding and surgical prophylaxis in patients with afibrinogenemia.

General Coagulation Management Applications Generate Stable Revenue Streams for Stakeholders

The fibrinogen concentrates market is expected to reach a valuation of US$ 700 Mn by 2031. The concept of targeted point-of-care bleeding management is becoming a fast growing phenomenon in the market landscape. Emerging studies are making use of fibrinogen, also known as factor I, in lieu of whole blood to facilitate clotting. Fibrinogen concentrates are being highly publicized for the management of bleeding events, since it allows the administration of a precise dose to reach a desired target level.

Manufacturers in the fibrinogen concentrates market are making products and treatments easily available for hospitals, ambulatory surgical centers, and other healthcare systems. General coagulation management applications are expected to register the highest revenue share among all application types.

Early Coagulation Therapy Holds Promising Potentials to Improve Survival Rate of Patients

The early fibrinogen concentrate administration is being preferred in complex and time-sensitive environment of pre-hospital trauma care. This helps to protect against early fibrinogen depletion, promotes rapid blood clot initiation, and clot stability. Such trends are translating into value-grab opportunities for stakeholders in the fibrinogen concentrates market.

The presence of trauma-induced coagulopathy (TIC) in severely injured and bleeding patients on admission to the emergency department (ED) is leading to increased mortality rates. In order to lower mortality rates, companies are bolstering their production capabilities to ensure the readily available treatments and products. Early and effective coagulation therapy holds promising potentials to improve survival in patients. As such, manufacturers in the fibrinogen concentrates market are gaining evidence that supports early fibrinogen supplementation in trauma patients. There is a growing demand for fibrinogen concentrate products in highly dynamic and complex environment of acute pre-hospital trauma care.

Fibrinogen Concentrate Help Decrease Bleeding Tendency, Reduce Transfusion Requirements

A significant number of deaths attributable to hemorrhage occur within the first hour of hospital arrival. This is emerging as a key driver of growth in the fibrinogen concentrates market. There is an increased emphasis on hemostatic resuscitation in pre-hospital settings and battlefield. The concept of remote damage control resuscitation (RDCR) is growing popular in the fibrinogen concentrates market, which imposes logistic challenges and requirement for hemostatic products that can be easily stored, transported, and used in the field austere environment. Thus, manufacturers are tapping into revenue opportunities in such innovative and lesser-known applications.

There is evidence that shows fibrinogen concentrate has the capability to reduce transfusions of blood products and increase survival rates of patients after severe trauma. Stakeholders are anticipated to collaborate with researchers to gain evidence via randomized controlled trials to assess how fibrinogen concentrate help to decrease bleeding tendency and reduce transfusion requirements.

Generation of Strong Data Boosts Application of Fibrinogen Concentrates for TIC

Since trauma is the leading cause of mortality with major bleeding and trauma-induced coagulopathy (TIC), fibrinogen concentrate is being publicized as the first line of treatment for TIC. Contributing factors such as initiatives to improve TIC management, generation of stronger data, and improved medical education are of paramount importance to increase better patient outcomes. Simplified practice guidance and improved access to viscoelectic testing are forming critical factors for growth of the fibrinogen concentrates market.

TIC requires different treatment strategies, which include tranexamic acid (TXA), human fibrinogen concentrate, and prothrombin complex concentrates (PCCs), among others. Manufacturers in the fibrinogen concentrates market are gaining awareness about such patient demands and requirements from healthcare systems.

Education, Network Building Significant for Improvement in Blood Products

Canadian Blood Services - a provider of lifesaving products and services in transfusion and transplantation for patients is gaining recognition for continuously improving blood products and their utilization, which results in improvement of patient quality of life. Stakeholders in the fibrinogen concentrates market are taking cues from such developments to build their network of scientists, medical experts, collaborators, and research partners to improve blood products.

Guided clinical practices are supporting national studies, which suggest that fibrinogen concentrate is equivalent to cryoprecipitate in controlled post-operative bleeding. Such insights are impacting the way cardiac patients can be treated in various healthcare facilities. Stakeholders are realizing the importance of R&D, training, education, and engagement activities that play a key role in improving blood products. On the other hand, fibrinogen concentrate is being preferred over fresh frozen plasma (FFP), since the former delivers a standardized and higher concentration of coagulation proteins.

Market Segmentation: Fibrinogen Concentrates Market

• In terms of application, the global fibrinogen concentrates market has been classified into general coagulation management, surgery, and others
• Based on end user, the global fibrinogen concentrates market has been divided into hospitals, ASCs, and others
• Each of the segments has been analyzed in detail for trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The fibrinogen concentrates market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2030, considering 2021 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2030, along with market size estimations.

Regional Overview: Fibrinogen Concentrates Market

• In terms of region, the global fibrinogen concentrates market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
• Europe held a significant share of the global fibrinogen concentrates market in 2021, followed by North America. Europe is likely to retain market share during the forecast period. High awareness about the availability of different brands of fibrinogen concentrate products and early introduction of fibrinogen concentrates drive the market in the region.
• Asia Pacific is likely to gain market share during the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by players, especially in China and Japan, are projected to propel the fibrinogen concentrates market in the region.
• Current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the fibrinogen concentrates market report for the period from 2017 to 2030, along with their CAGRs for the period from 2020 to 2030
• The study also offers a list of recommendations, highlights, and useful insights of the market, which are likely to help new companies willing to enter the fibrinogen concentrates market and existing companies to increase market share and in the decision-making process

Some of the prominent players in the Fibrinogen Concentrates Market include:

• CSL Behring
• Baxter
• Johnson & Johnson (Ethicon)
• LFB Group
• ProFibrix BV (The Medicines Company)
• Shanghai RAAS
• Jiangxi Boya Bio-Pharmaceutical
• Hualan Biological Engineering
• Harbin Pacific Biopharmaceutical
• Greencross

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Fibrinogen Concentrates market

By Type

• Human
• Animal

Application

• General Coagulation Management
• Surgery
• Others

End User

• Hospitals
• ASCs
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Fibrinogen Concentrates industry analysis from 2022 to 2030 to identify the prevailing Fibrinogen Concentrates industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Fibrinogen Concentrates industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Fibrinogen Concentrates industry trends, key players, market segments, application areas, and market growth strategies.